Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration. [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 trial comparing KSI-301, a biopolymer-conjugated anti-VEGF antibody, against aflibercept in wet age-related macular degeneration was terminated,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)
• KSI-301 (KSI-301)

Snippet

Sponsor: Kodiak Sciences Inc | Conditions: Wet Macular Degeneration | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2024-07-18